Ask the Expert: A Live Session with Dr. Michael Hochman for the MDS Community image

Ask the Expert: A Live Session with Dr. Michael Hochman for the MDS Community

Jun 17, 2026
01:00PM - 02:00PM EDT
Online Event
Overview

Join the HealthTree Foundation for MDS for an intimate Q&A session with Dr. Michael Hochman to gain clarity on your diagnosis and the latest clinical updates. We invite you to pre-submit your questions so we can focus on the topics most important to your health and care. Please note this event is for educational purposes and does not provide individualized medical advice or treatment.

 SUBMIT YOUR QUESTIONS HERE

Agenda
1:00 PM
Introduction
Dalton Bean

Dalton introduces the agenda for the event and the speaker Michael Hochman

1:05 PM
Questions & Answers
Michael Hochman

Come with your questions for Michael Hochman, MD

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Healthtree contact Michael Hochman

Michael Hochman

A board certified hematologist, Dr. Hochman treats patients with acute leukemia, myelodysplastic neoplasms and other myeloid malignancies. Dr. Hochman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. Dr. Hochman received his Medical Degree from Duke University School of Medicine in Durham, North Carolina. He completed his residency at University of Washington Affiliated Hospitals in Seattle, Washington. He completed his fellowship in hematology at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he served as Chief Fellow in his final year. Dr. Hochman's research focuses on developing novel therapeutic strategies for treatment of myeloid malignancies, including new drugs and drug combinations. He is also studying the use of new technologies to better predict treatment outcomes and assess measurable residual disease among clonal myeloid disorders.